The list of medicines of high clinical value, published on August 26, 2021, includes 35 medical technologies – including 30 medicinal products registered by #EMA in 2017-2020.
In the period from 01/01/2017 to 31/12/2020, 951 drug technologies (for 321 medicinal products) were registered by EMA. The final list was selected by #AOTMiT from 374 medical technologies (39%) left after the exclusion of currently reimbursed options. Technologies included in the final list constitute 9.4% of drug technologies qualified for the assessment by AOTMiT.
Among 35 selected technologies, 31% have oncological indications, and 43% have the status of an orphan drug, which suggests that, as announced, these indications are the main priority for the Medical Fund.
17 drug technologies can be used in children and adults, while 18 drug technologies can only be used in adults.